STOCKHOLM, Nov. 7, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT)(Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in the following conferences:
CEO Renée Aguiar-Lucander will also be speaking on a panel on Day 2 of the FT Global Pharma & Biotech Summit, which is taking place in November 7 - 9 2023 in London, UK. The Panel `Exploring Options for Strategic Partnerships' will take place at 11:05am GMT on Wednesday 8 November.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
The information was sent for publication, through the agency of the contact persons set out above, on November 7, 2023, at 16:00 p.m. CET.
The following files are available for download:
Conferences Press Release ENG |
Last Trade: | US$40.00 |
Daily Volume: | 0 |
Market Cap: | US$1.080B |
August 13, 2024 July 26, 2024 June 18, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB